TLC D-99 liposomal doxorubicin data

LIPO (Princeton, N.J.) announced Phase II data showing that 30 of 41 patients responded to the agent when it was combined with two other anti-cancer agents in common use. Complete tumor remission was seen in two patients, and a partial tumor regression in 28.

Two Phase III trials are underway testing the agent as a first line treatment. ...